ENLV

Enlivex Therapeutics Ltd. [ENLV] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

ENLV Stock Summary

Top 10 Correlated ETFs

ENLV


Top 10 Correlated Stocks

ENLV


In the News

08:00 29 Sep 2023 ENLV

Enlivex to Present at the 2023 Jefferies Healthcare Conference

Nes-Ziona, Israel, June 06, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company management will present a corporate update at the 2023 Jefferies Healthcare Conference, which is taking place at the Marriott Marquis in New York, NY. The presentation will take place on June 9, 2022, at 11:30 AM Eastern Time. A webcast of the presentation will be available at https://wsw.com/webcast/jeff281/enlv/1860430, and will be archived for 90 days.

08:13 29 Sep 2023 ENLV

Enlivex to Present at the 4th Macrophage-Directed Therapies Summit

Nes-Ziona, Israel, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company management will participate in, and present at, the 4th Macrophage-directed Therapies Summit, which is taking place in Boston, Massachusetts from October 4-6, 2022.

02:08 29 Sep 2023 ENLV

Enlivex Therapeutics: A Very Enticing Early-Stage Biotech

Enlivex Therapeutics: The early results for Allocetra for sepsis (in humans) and solid tumors (in mice) look incredible. The share offering from 2021 shows a willingness to protect existing shareholders.

08:00 29 Sep 2023 ENLV

Enlivex to Present at the 2022 Jefferies Healthcare Conference

Nes-Ziona, Israel, June 07, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis and solid tumors, today announced that company management will present a corporate update at the 2022 Jefferies Healthcare Conference, which is taking place at the Marriott Marquis in New York, NY. The presentation will take place on June 9, 2022, at 1:00 PM Eastern Time. A webcast of the presentation will be available at https://wsw.com/webcast/jeff240/enlv/1853925 , and will be archived for 90 days.

10:48 29 Sep 2023 ENLV

Enlivex Therapeutics Stock (ENLV): Why The Price Increased Today

The stock price of Enlivex Therapeutics Ltd (NASDAQ: ENLV) increased by over 4% during intraday trading today. This is why it happened.

08:00 29 Sep 2023 ENLV

Enlivex CSO Prof. Dror Mevorach Publishes Foundational Paper on the Pfizer–BioNTech COVID-19 Vaccine in The New England Journal of Medicine

Publication follows the Israeli Ministry of Health's appointment of Prof. Mevorach as the lead investigator of a team evaluating side effects of COVID-19 vaccines

08:48 29 Sep 2023 ENLV

Enlivex to Present at Reuters Events' Cell & Gene Therapy USA 2021

Nes-Ziona, Israel, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company management will participate in, and present at, the Reuters Events' Cell & Gene Therapy USA 2021 event, which is taking place virtually on September 28 and 29, 2021.

07:45 29 Sep 2023 ENLV

Enlivex Therapeutics (ENLV) Sees Hammer Chart Pattern: Time to Buy?

Enlivex Therapeutics (ENLV) has been struggling lately, but the selling pressure may be coming to an end soon.

11:27 29 Sep 2023 ENLV

Enlivex (ENLV) Begins Phase IIb COVID-19 Study on Cell Therapy

Enlivex (ENLV) doses the first patient in a phase IIb study evaluating its cell therapy, Allocetra, in severe and critical COVID-19 patients with acute respiratory distress syndrome.

06:00 29 Sep 2023 ENLV

Enlivex Doses First Patient in Placebo-Controlled Phase IIb Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients with ARDS



ENLV Financial details

Company Rating
Buy
Market Cap
27.15M
Income
-26.77M
Revenue
0
Book val./share
2.39
Cash/share
1.56
Dividend
-
Dividend %
-
Employees
71
Optionable
No
Shortable
Yes
Earnings
15 Dec 2023
P/E
-1.04
Forward P/E
-
PEG
-0.06
P/S
-
P/B
0.63
P/C
1
P/FCF
-0.99
Quick Ratio
6.17
Current Ratio
6.17
Debt / Equity
0.1
LT Debt / Equity
0.08
-
-
EPS (TTM)
-1.45
EPS next Y
-
EPS next Q
-
EPS this Y
327.78%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-9.76%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-33.33%
Inst Own
1.64%
Inst Trans
0.88%
ROA
-50%
ROE
-50%
ROC
-0.56%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
18.6M
Shs Float
14.5M
-
-
-
-
Target Price
15
52W Range
1.4503-4.92
52W High
-61%
52W Low
+56%
RSI
25
Rel Volume
0.18
Avg Volume
23.82K
Volume
4.4K
Perf Week
-0.64%
Perf Month
-37.85%
Perf Quarter
-44.29%
Perf Half Y
-54.78%
-
-
-
-
Beta
0.594689
-
-
Volatility
0.06%, 0.37%
Prev Close
4%
Price
1.56
Change
-2.34%

ENLV Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
Revenue per share
000.1700
Net income per share
-1.21-1.17-1.05-0.54-2.31
Operating cash flow per share
-0.9-0.81-0.84-0.98-1.3
Free cash flow per share
-1.03-0.84-0.91-1.07-1.74
Cash per share
2.791.392.714.712.62
Book value per share
2.771.32.694.763.09
Tangible book value per share
2.771.262.694.763.09
Share holders equity per share
2.771.32.694.763.09
Interest debt per share
00.010.020.030.55
Market cap
21.72M72.57M111.02M111.62M72.48M
Enterprise value
11.99M68.74M105.55M101.04M29.5M
P/E ratio
-5.12-7.15-8.01-11.57-1.71
Price to sales ratio
0048.7600
POCF ratio
-6.87-10.31-10.09-6.36-3.03
PFCF ratio
-6-10.03-9.23-5.82-2.26
P/B Ratio
2.246.433.131.311.28
PTB ratio
2.246.433.131.311.28
EV to sales
0046.3500
Enterprise value over EBITDA
-1.97-9.27-14.58-4.25-1.56
EV to operating cash flow
-3.79-9.76-9.59-5.76-1.23
EV to free cash flow
-3.31-9.5-8.78-5.27-0.92
Earnings yield
-0.2-0.14-0.12-0.09-0.59
Free cash flow yield
-0.17-0.1-0.11-0.17-0.44
Debt to equity
00.010.010.010.09
Debt to assets
00.010.010.010.07
Net debt to EBITDA
1.60.520.760.452.27
Current ratio
9.092.758.7218.327.92
Interest coverage
0000-4.9
Income quality
0.750.750.931.210.77
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
001.5800
Research and developement to revenue
002.6700
Intangibles to total assets
00.02000
Capex to operating cash flow
0.150.030.090.090.34
Capex to revenue
00-0.4500
Capex to depreciation
-3.81-0.94-3.56-2.98-10.45
Stock based compensation to revenue
000.2900
Graham number
8.675.877.997.6112.66
ROIC
-0.68-0.81-0.32-0.15-0.56
Return on tangible assets
-0.38-0.59-0.34-0.1-0.63
Graham Net
2.450.871.223.92.09
Working capital
9.15M10.44M33.75M81.72M45.72M
Tangible asset value
9.71M10.87M35.49M85.04M56.84M
Net current asset value
8.95M10.14M33.25M76.34M41.53M
Invested capital
00.010.010.010.09
Average receivables
120.5K1.31M1.78M1.68M1.42M
Average payables
96K244.5K389.5K670.5K1.41M
Average inventory
00-15.6M-21.7M-5.51M
Days sales outstanding
00186.5900
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
001.9600
Payables turnover
00000
Inventory turnover
00000
ROE
-0.44-0.9-0.39-0.11-0.75
Capex per share
-0.13-0.02-0.08-0.09-0.44

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric History 2022-06-302022-09-302022-12-312023-03-31 2023-06-30
Revenue per share
00000
Net income per share
-0.76-0.31-0.36-0.41-0.37
Operating cash flow per share
-0.5-0.36-0.26-0.31-0.38
Free cash flow per share
-0.69-0.42-0.4-0.32-0.38
Cash per share
3.42.12.621.941.56
Book value per share
3.733.443.092.732.39
Tangible book value per share
3.733.443.092.732.39
Share holders equity per share
3.733.443.092.732.39
Interest debt per share
0.250.290.230.280.24
Market cap
83.06M78.17M72.48M67.4M48.7M
Enterprise value
63.53M44.87M29.5M58.94M49.61M
P/E ratio
-1.49-3.38-2.77-2.2-1.79
Price to sales ratio
00000
POCF ratio
-8.96-11.86-15.04-11.65-6.93
PFCF ratio
-6.55-10.04-9.8-11.34-6.9
P/B Ratio
1.211.241.281.331.1
PTB ratio
1.211.241.281.331.1
EV to sales
00000
Enterprise value over EBITDA
-11.16-8.18-3.87-8.97-7.71
EV to operating cash flow
-6.85-6.81-6.12-10.19-7.06
EV to free cash flow
-5.01-5.77-3.99-9.91-7.03
Earnings yield
-0.17-0.07-0.09-0.11-0.14
Free cash flow yield
-0.15-0.1-0.1-0.09-0.14
Debt to equity
0.010.080.090.090.1
Debt to assets
0.010.070.070.080.08
Net debt to EBITDA
3.436.075.641.29-0.14
Current ratio
15.4413.087.926.896.17
Interest coverage
-1.45-101.3811.96-15.590
Income quality
0.941.150.670.81.03
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0.370.180.540.030.01
Capex to revenue
00000
Capex to depreciation
-19.31-6.2-11.68-0.78-0.18
Stock based compensation to revenue
00000
Graham number
7.984.944.975.044.45
ROIC
-0.12-0.08-0.11-0.12-0.13
Return on tangible assets
-0.18-0.08-0.1-0.13-0.13
Graham Net
3.022.182.091.51.17
Working capital
60.84M54.7M45.72M32.13M25.79M
Tangible asset value
68.49M63.27M56.84M50.57M44.34M
Net current asset value
56.2M50.09M41.53M28.13M22.09M
Invested capital
0.010.080.090.090.1
Average receivables
1.82M1.96M1.06M1.13M1.74M
Average payables
1.01M861.5K1.5M1.72M1.52M
Average inventory
09.55M10.14M588.5K0
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.2-0.09-0.11-0.15-0.15
Capex per share
-0.18-0.06-0.14-0.010

ENLV Frequently Asked Questions

What is Enlivex Therapeutics Ltd. stock symbol ?

Enlivex Therapeutics Ltd. is a IL stock and trading under the symbol ENLV

Is Enlivex Therapeutics Ltd. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $15. The lowest prediction is $15 and the highest is $15

What is ENLV stock prediction ?

What is Enlivex Therapeutics Ltd. stock quote today ?

Enlivex Therapeutics Ltd. stock price is $1.56 today.

Is Enlivex Therapeutics Ltd. stock public?

Yes, Enlivex Therapeutics Ltd. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap